

**Table S1** Factors associated with OS in patients with stage IIB thymoma before PSM

Factors	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P	HR (95% CI)	P
<b>Age</b>				
<65 years	1.000 (reference)		1.000 (reference)	
≥65 years	3.686 (2.204, 6.166)	<0.001	4.644 (2.705, 7.971)	<0.001
<b>Gender</b>				
Male	1.000 (reference)		–	–
Female	0.831 (0.503, 1.370)	0.46	–	–
<b>Race</b>				
White	1.000 (reference)		–	–
Black	0.989 (0.445, 2.198)	0.97	–	–
Others	0.682 (0.352, 1.321)	0.25	–	–
<b>WHO histology</b>				
Low risk	1.000 (reference)		1.000 (reference)	
High risk	1.848 (1.007, 3.389)	0.047	2.407 (1.292, 4.484)	0.006
NOS	1.668 (0.903, 3.081)	0.10	1.880 (1.005, 3.517)	0.048
<b>Chemotherapy</b>				
No	1.000 (reference)		1.000 (reference)	
Yes	1.136 (0.337, 3.828)	0.83	1.713 (0.496, 5.912)	0.39
Unknown	1.682 (0.953, 2.967)	0.07	2.110 (1.174, 3.793)	0.01
<b>Tumor size</b>				
<5.5 cm	1.000 (reference)		–	–
≥5.5 cm	1.032 (0.603, 1.767)	0.90	–	–
Unknown	0.523 (0.122, 2.241)	0.38	–	–
<b>PORT</b>				
No	1.000 (reference)		1.000 (reference)	
Yes	0.919 (0.551, 1.532)	0.74	1.150 (0.677, 1.952)	0.60

OS, overall survival; PSM, propensity score matching; HR, hazard ratio; CI, confidence interval; WHO, World Health Organization; NOS, not otherwise specified; PORT, postoperative radiotherapy.

**Table S2** Factors associated with CSS in patients with stage IIB thymoma before PSM

Factors	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P	HR (95% CI)	P
<b>Age</b>				
<65 years	1.000 (reference)		–	–
≥65 years	1.581 (0.442, 5.654)	0.48	–	–
<b>Gender</b>				
Male	1.000 (reference)		–	–
Female	1.024 (0.296, 3.541)	0.97	–	–
<b>Race</b>				
White	1.000 (reference)		–	–
Black	2.188 (0.441, 10.845)	0.33	–	–
Others	0.931 (0.188, 4.614)	0.93	–	–
<b>WHO histology</b>				
Low risk	1.000 (reference)		1.000 (reference)	
High risk	1.209 (0.202, 7.238)	0.83	1.156 (0.187, 7.162)	0.87
NOS	3.113 (0.742, 13.052)	0.12	2.686 (0.634, 11.386)	0.18
<b>Chemotherapy</b>				
No	1.000 (reference)		1.000 (reference)	
Yes	3.913 (0.352, 43.522)	0.26	3.414 (0.297, 39.287)	0.32
Unknown	3.252 (0.646, 16.379)	0.15	2.603 (0.500, 13.557)	0.25
<b>Tumor size</b>				
<5.5 cm	1.000 (reference)		–	–
≥5.5 cm	1.873 (0.389, 9.028)	0.43	–	–
Unknown	2.764 (0.249, 30.652)	0.40	–	–
<b>PORT</b>				
No	1.000 (reference)		1.000 (reference)	
Yes	2.331 (0.495, 10.979)	0.28	2.159 (0.455, 10.237)	0.33

CSS, cancer-specific survival; PSM, propensity score matching; HR, hazard ratio; CI, confidence interval; WHO, World Health Organization; NOS, not otherwise specified; PORT, postoperative radiotherapy.

**Table S3** Baseline characteristics before and after PSM for Asians

Characteristics	Before PSM			After PSM		
	Non-PORT (n=23), n (%)	PORT (n=38), n (%)	P	Non-PORT (n=18), n (%)	PORT (n=18), n (%)	P
Age			0.34			>0.99
<65 years	15 (65.2)	29 (76.3)		14 (77.8)	14 (77.8)	
≥65 years	8 (34.8)	9 (23.7)		4 (22.2)	4 (22.2)	
Gender			0.19			>0.99
Male	10 (43.5)	23 (60.5)		8 (44.4)	8 (44.4)	
Female	13 (56.5)	15 (39.5)		10 (55.6)	10 (55.6)	
WHO histology			0.39			0.33
Low risk	12 (52.2)	15 (39.5)		7 (38.9)	8 (44.4)	
High risk	5 (21.7)	15 (39.5)		5 (27.8)	8 (44.4)	
NOS	6 (26.1)	8 (21.1)		6 (33.3)	2 (11.1)	
Chemotherapy			0.91			>0.99
No	15 (65.2)	23 (60.5)		11 (61.1)	12 (66.7)	
Yes	2 (8.7)	3 (7.9)		1 (5.6)	0 (0.0)	
Unknown	6 (26.1)	12 (31.6)		6 (33.3)	6 (33.3)	
Tumor size			0.81			>0.99
<5.5 cm	8 (34.8)	16 (42.1)		7 (38.9)	7 (38.9)	
≥5.5 cm	14 (60.9)	20 (52.6)		10 (55.6)	10 (55.6)	
Unknown	1 (4.3)	2 (5.3)		1 (5.6)	1 (5.6)	

PSM, propensity score matching; PORT, postoperative radiotherapy; NOS, not otherwise specified.